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Abstract
The family Flaviviridae includes viruses that have different virion structures and morphogen-
esis mechanisms. Most cellular and molecular studies have been so far performed with
viruses of the Hepacivirus and Flavivirus genera. Here, we studied bovine viral diarrhea
virus (BVDV), a member of the Pestivirus genus. We set up a method to purify BVDV virions
and analyzed their morphology by electron microscopy and their protein and lipid composi-
tion by mass spectrometry. Cryo-electron microscopy showed near spherical viral particles
displaying an electron-dense capsid surrounded by a phospholipid bilayer with no visible
spikes. Most particles had a diameter of 50 nm and about 2% were larger with a diameter of
up to 65 nm, suggesting some size flexibility during BVDV morphogenesis. Morphological
and biochemical data suggested a low envelope glycoprotein content of BVDV particles, E1
and E2 being apparently less abundant than Erns. Lipid content of BVDV particles displayed
a ~2.3 to 3.5-fold enrichment in cholesterol, sphingomyelin and hexosyl-ceramide, concomi-
tant with a 1.5 to 5-fold reduction of all glycerophospholipid classes, as compared to lipid
content of MDBK cells. Although BVDV buds in the endoplasmic reticulum, its lipid content
differs from a typical endoplasmic reticulum membrane composition. This suggests that
BVDV morphogenesis includes a mechanism of lipid sorting. Functional analyses con-
firmed the importance of cholesterol and sphingomyelin for BVDV entry. Surprisingly,
despite a high cholesterol and sphingolipid content of BVDV envelope, E2 was not found in
detergent-resistant membranes. Our results indicate that there are differences between the
structure and molecular composition of viral particles of Flaviviruses, Pestiviruses and
Hepaciviruses within the Flaviviridae family.
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Author Summary
Bovine viral diarrhea virus (BVDV) is the etiologic agent of mucosal disease and bovine
viral diarrhea, two economically important diseases of the livestock. BVDV is a member of
the Pestivirus genus in the Flaviviridae family, which also includes Hepacivirus and Flavi-
virus genera. Members of this family share similar genome organization and replication
strategies, but differ about their mode of transmission and particle structure. Whereas
most studies have been so far performed on viruses of the Hepacivirus and Flavivirus gen-
era, little is known about infectious particles of pestiviruses. In this study, we set up a novel
purification method of BVDV infectious particles and analyzed their morphology by cryo-
electron microscopy and their molecular composition by mass spectrometry. Our results
provide new insights into the structure and biochemical composition of a pestivirus infec-
tious particle, and have implications for research on molecular mechanisms of their mor-
phogenesis and entry.
Introduction
The Flaviviridae family includes important human and animal pathogens. Members of this
family are enveloped, positive-stranded RNA viruses that share similarities in replication and
genome organization. They have been classified into 4 genera, namely Flavivirus, Hepacivirus,
Pestivirus and Pegivirus. The Flavivirus genus consists of a large number of arthropod-borne
viruses. The Hepacivirus genus includes hepatitis C virus (HCV) and recently identified closely
related viruses. Members of the Pestivirus genus are animal pathogens including bovine viral
diarrhea virus (BVDV), classical swine fever virus (CSFV) and border disease virus (BDV) of
sheep [1]. The Pegivirus genus contains a few HCV-related viruses, formerly known as GB-
viruses.
Despite similarities in genome organization and replication mechanisms, members of this
family have very different modes of transmission: most flaviviruses are transmitted by mosqui-
toes or ticks, while the mode of transmission of pestiviruses can be oro-nasal and diaplacental
and that of HCV is parenteral. These differences in transmission mode are mirrored by differ-
ences in the structure of infectious particles and envelope proteins of flaviviruses and hepaci-
viruses. Flavivirus infectious virions are ~50 nm particles fully coated with 90 dimers of class II
envelope protein E [2,3]. In contrast, HCV particles have been proposed to display a lipopro-
tein-like structure [4,5] containing high amounts of apolipoproteins, especially apoE [6,7].
These different structural organizations denote differences in morphogenesis mechanisms.
Envelope proteins appear to be a major driving force of flaviviruses morphogenesis, yielding
both infectious particles and non-infectious, capsid-less, sub-viral particles. In contrast, the
release of sub-viral particles from pestivirus-infected cells has not been reported. Capsid-less
particle release by HCV-infected hepatocytes has been reported [8]. However this most proba-
bly reflects the incorporation of E1E2 envelope glycoproteins in apoB-containing lipoproteins
[9], rather than the production of flavivirus-like sub-viral particles. Indeed, HCV appears to
contain a limited number of envelope glycoproteins per virion [6,7], precluding any role in
driving the budding process. HCV morphogenesis is proposed to be aided by the machinery of
VLDL formation of hepatocytes [4]. This results in the production of infectious particles of low
buoyant density reflecting a high content in neutral lipids cholesteryl ester [6] and probably
also triacylglycerol. Remarkably, recent reports also indicate that the structures of envelope
proteins E2 of BVDV and HCV are radically different from each other and from class II pro-
teins of flaviviruses [10–13].
BVDV Purification
PLOS Pathogens | DOI:10.1371/journal.ppat.1005476 March 3, 2016 2 / 30
For pestiviruses, much less is known concerning the structure of the virions and the mecha-
nisms of morphogenesis [14]. Electron microscopy images of BVDV-infected cells have
revealed the presence of small enveloped ~50 nm viral particles of irregular form [15] budding
in the ER membrane [16]. Pestivirus virions produced in cell culture have buoyant densities of
1.10–1.13 g/cm3 in sucrose gradients [17–19], intermediate between those of flaviviruses (1.19–
1.23 g/cm3) and HCV (1.05–1.10 g/cm3) [1]. Moreover, it has recently been demonstrated that
core, the capsid protein, is not essential for the release of infectious CSFV particles [17]. All
these observations suggest that pestiviruses have a virion structure and morphogenesis mecha-
nisms that differ from those of HCV and flaviviruses. To address this question, we set up a
method of purification of BVDV virions and analyzed their morphology by cryo-electron
microscopy and their protein and lipid content by mass spectrometry.
Results
Purification of BVDV particles
Viral particles were purified from culture medium of MDBK cells infected with a non-cyto-
pathic strain of BVDV in order to reduce the presence of apoptotic bodies and other cell-
derived debris, which are released in high amounts during an infection with a cytopathic strain.
Four steps were required in order to obtain a purified virus. Viral particles were precipitated
with PEG and separated from heavy membranes and from soluble material by centrifugation
through two cushions of 15 and 30% sucrose. The infectious material was found in a fraction
located just below the 15–30% interface. The virus was further purified by flotation in a sucrose
density gradient. Viral proteins were detected by immunoblotting and the infectivity of each
fraction of the gradient was measured. A single peak of C, Erns, E1 and E2 proteins was detected
in the gradient (Fig 1A), which matched the distribution of infectious particles (Fig 1B). E1 and
E2 were detected as single bands, whereas Erns appeared as a smear or multiple bands, likely
representing heterogeneity of Erns-associated glycan structure. C was detected as two bands.
However, it is not clear if this actually represents post-translational modification or limited
degradation of the protein, because the doublet was not consistently observed. The buoyant
density of this peak was measured as 1.125 ± 0.006 g/cm3 (n = 5, mean ± SD). This value is con-
sistent with previously reported buoyant density values of infectious BVDV particles from par-
tially purified or unpurified sources [18,19]. Finally, most of the remaining membranous
contaminants were removed with a chromatography step on cellulose-sulfate beads. At each
purification step, viral particles were quantified both by infectious titer and core immunoblot-
ting. Typically, starting from about 900 ml of culture medium titrating approximately 106−107
ffu/ml, this method yielded 50 μl of purified virus with a titer in the range of 1010−1011 ffu/ml.
Analysis of purified BVDV particles by cryo-electron microscopy
Examination of purified fractions by electron microscopy after negative staining revealed the
presence of numerous particles of about 50 nm and a few contaminating objects (Fig 2A). At
higher magnification, 50-nm particles appeared more or less spherical (Fig 2B). For a better
preservation of BVDV morphology, purified particles were observed by cryo-electron micros-
copy, a technique that preserves the hydration state of the sample and avoids dehydration arti-
fact induced by negative staining. Again, the more abundant objects were spherical particles
with a diameter of about 50 nm (Fig 2C and 2D and S1 Fig). These objects were absent from
samples purified from uninfected cells (S2 Fig). They were bounded by two electron-dense thin
layers with a clear layer in between, which likely represent the lipid bilayer of the viral envelope.
The inner part of the viral particles was made of electron-dense material, likely corresponding
to the viral capsid. The preparation also contained some smaller (30–35 nm) non-enveloped
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objects of the same size and morphology as viral capsids, a small number of larger (55–65 nm)
virus-like particles and other unrelated objects (Fig 2C and 2D).
We could not find any clear morphological evidence for the presence of envelope glycopro-
teins at the surface of viral particles using cryo-electron microscopy. We performed immuno-
gold labeling of purified BVDV under negative staining condition, but surprisingly very few
viral particles were labeled (S3 Fig). To verify that anti-E2 antibodies actually recognize E2 gly-
coproteins present on purified viral particles, we analyzed their neutralization potency. No sig-
nificant difference of neutralization curves (IC50 = 3.44 ng/ml and 3.53 ng/ml for unpurified
and purified BVDV, respectively) was observed between unpurified and purified BVDV (S4
Fig), suggesting that E2 glycoproteins were not altered during purification.
To confirm that the 50-nm particles actually are BVDV virions, purified material was incu-
bated with an antibody to BVDV glycoprotein E2 coupled to magnetic beads and the immuno-
captured material was visualized by cryo-electron microscopy. Magnetic beads covered with
anti-E2 antibodies captured 50-nm virus-like particles, thus confirming that these objects are
BVDV virions exposing E2 glycoprotein at their surface (Fig 3A). Occasionally, larger virus-
like particles could also be observed (Fig 3A), suggesting that they are viral particles of larger
size. Control beads with no antibody (Fig 3B) or with an irrelevant antibody (Fig 3C) did not
Fig 1. Flotation of BVDV particles in a sucrose density gradient. BVDV was collected from culture
medium of infected MDBK cells, concentrated by PEG precipitation, isolated in a 15–30% sucrose interface,
adjusted to 40% sucrose, overlaid with a 5–35% sucrose density gradient and centrifuged. Fractions were
collected from the bottom of the tube. (A) Immunoblot analysis of gradient fractions with indicated antibodies
under reducing conditions for C, E1 and Erns, and non-reducing conditions for E2. (B) Infectious titers and
buoyant density of gradient fractions.
doi:10.1371/journal.ppat.1005476.g001
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Fig 2. Analysis of purified BVDV particles by electron microscopy. Visualization of purified BVDV particles after negative staining (A, B), or by cryo-
electron microscopy (C, D). Black arrows: enveloped, capsid-containing particles of ~50 nm, black arrowheads: larger enveloped, capsid-containing
particles, white arrowheads: non-enveloped, capsid-like particles, white arrows: small empty vesicles, white asterisks: large vesicles. (E) Quantification of
BVDV Purification
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bind any particles. This result indicates that the 50-nm particles, as well as larger particles of
the same morphology expose BVDV E2 glycoprotein at their surface and thus confirms that
these particles actually are BVDV virions. Accordingly, these objects were not observed in con-
trol fractions purified from non-infected cells (S2 Fig), and very few of them were found in the
flow-through fraction of the chromatography step, which is enriched in contaminating mate-
rial (S5 Fig). Importantly, the contaminating material principally consisted of vesicles that are
structurally different from core-containing 50-nm particles of the purified fraction.
The purity of a virus preparation was evaluated by counting objects visible in cryo-electron
microscopy according to their morphology. Examples of objects that were counted are indi-
cated in Fig 2C and 2D. Among 1871 objects counted, 82% were 50-nm enveloped virions, 7%
non-enveloped core-like particles and 2% larger virions; 1% of the material was made of small
vesicles about the same size as a virion with no internal core and 2% were larger vesicles. Finally
6% were unrelated objects (Fig 2E). This suggests that this purified fraction contained at least
82% of viral particles, if one considers only the 50-nm enveloped particles, and up to 91% of
viral particle-related objects, if one considers small non-enveloped objects as virions that have
lost their envelope during the final purification step, and larger virus-like particles as viruses
containing a larger capsid. This indicates a residual contamination of about 9%.
In order to have a more defined view of BVDV particles, 160 images of viral particles with a
diameter of 50 nm were aligned. A few of them are shown in Fig 2F. The projection resulting
from this alignment is shown in Fig 2G. The average image clearly showed the lipid bilayer and
the internal capsid structure. As observed on individual viral particles, there was no evidence of
spikes or of any other proteins at the membrane surface. Moreover, the lipid bilayer of the
envelope was clearly visible as two distinct electron-dense layers on most particles (Fig 2C, 2D
and 2F and S1 Fig) and on the average image (Fig 2G), suggesting that this membrane is poor
in trans-membrane proteins, as observed on HIV virions [20] or HCV pseudoparticles [21].
We also tried to purify infectious particles of cytopathic strain NADL using the same proto-
col. However, the final pellet mainly contained contaminating vesicles of different sizes and
shapes and very few 50-nm capsid-containing virus-like BVDV particles (S6 Fig). Therefore
different objects indicated in C and D. (F) examples of images used for virion reconstruction. (G) Virion reconstructed by projecting 160 images of 50-nm
particles. Bars, 200 nm (A) or 100 nm (B,D).
doi:10.1371/journal.ppat.1005476.g002
Fig 3. Immunocapture of BVDV particles. Protein G-coated magnetic beads (asterisks) were incubated with anti-BVDV E2mAbs (A), no antibody (B), or
an irrelevant mAb (C) and purified BVDV fraction and observed by cryo-electron microscopy. Black arrows: enveloped, capsid-containing particles of ~50
nm, black arrowheads: larger enveloped, capsid-containing particles. Bar, 100 nm.
doi:10.1371/journal.ppat.1005476.g003
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this purification protocol is probably not suited for purifying BVDV particles from cytopathic
strains, which generate a large number of membranous contaminants during infection.
To try to better define NADL particles from contaminating vesicles, we treated purified
NADL particles at pH 5.1 in the presence of a reducing agent. Such a treatment has been shown
to induce fusion of BVDV bound to the surface of cells [22]. However, no change of morphology
was observed (S7 Fig), suggesting that the structure of envelope proteins were not modified, or
that they were present at low density on the virions and therefore difficult to observe.
Dimerization of envelope proteins
Pestiviruses are endowed with envelope glycoproteins that are engaged in covalent homo- and
heterodimers [23,24]. During the purification, the detection of a single E2-immunoreactive
band of about 75 kDa in non-reduced virus samples (Fig 1A) suggested the presence of virion-
associated covalent E1E2 heterodimers, but no band corresponding to E2 monomer (~55 kDa)
or covalent homodimer (~110 kDa) could be observed. To assess whether our anti-E2 antibody
could detect E2 monomers and homodimers, we probed a lysate of infected MDBK cells under
reducing and non-reducing conditions. Three bands were detected with sizes of about 55, 75
and 110 kDa, consistent with the presence of E2 monomer, covalent E1E2 heterodimers and
covalent E2 homodimers respectively in infected MDBK cells (Fig 4A). None of these bands
was detected in non-infected cells lysate. Only one band was detected in reduced sample (Fig
4A). This band had an apparent size close to that of the 55-kDa band detected under non-
reducing condition, confirming its being E2 monomer. A slight difference of migration of E2
monomer under reducing and non-reducing conditions was observed, as previously reported
[23]. This likely reflects changes in the conformation of the glycoproteins induced by the
reducing agent. A more compact conformation of the native protein, resulting from the pres-
ence of intramolecular disulfide bridges, would explain its faster migration. These data con-
firmed that the anti-E2 antibodies we used are able to detect E2 monomer, homodimers and
heterodimers.
Fig 4. Envelope glycoprotein dimerization. (A) Triton-X100 lysates of infected and non-infected MDBK cells analyzed by immunoblot with a mix of anti-E2
mAbsWB214 andWB166 under reduced or non-reduced conditions. (B) Purified BVDV analyzed by immunoblot with anti-E2 mAbsWB214 andWB166,
anti-E1 mAb 8F2 or anti-Erns pAb under reduced (R) or non-reduced (NR) conditions. (C) Lysates of purified BVDV and infected MDBK cells containing
similar amounts of E1E2 heterodimer, and a lysate of non-infected MDBK cells were analyzed by immunoblot with anti-E2 mAbs under non-reduced
condition. The bands of E2 monomer, E2 homodimer and E1E2 heterodimer are indicated.
doi:10.1371/journal.ppat.1005476.g004
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Purified virus samples were probed under reducing and non-reducing conditions. Anti-E1
and anti-E2 antibodies detected a band of the same size (~75 kDa) under non-reducing condi-
tion (Fig 4B). Under reducing conditions, an anti-E1 antibody revealed a band of 25 kDa, the
expected size of E1 monomer, and an anti-E2 antibody revealed a band of 55 kDa, which is the
size of E2 monomer observed in cell lysates. This confirmed that the 75-kDa band is a covalent
E1E2 heterodimer. On the other hand, we detected bands of different size and aspect with anti-
Erns antibody than with E1 and E2 antibodies in non-reduced samples, indicating the absence
of covalent E1Erns or E2Erns heterodimers. Single bands of ~90–100 kDa and ~45–50 kDa were
detected under non-reducing and reducing conditions, respectively, consistent with the pres-
ence of covalent Erns homodimer in pestivirus virions, as reported previously [25,26].
To further assess the potential presence of E2 homodimer and E2 monomer on BVDV par-
ticles, lysates of partially purified BVDV (flotation gradient fraction) and of infected MDBK
cells containing similar amounts of E1E2 heterodimer were analyzed by immunoblot under
non-reducing condition. No band corresponding to E2 homodimer or E2 monomer could be
observed even after prolonged exposure of the blot (Fig 4C). Scanning and quantification of
the bands indicated that the amounts of E2 homodimer and monomer on BVDV particles are
less than 0.3% of E1E2 heterodimer.
In contrast, E2 homodimer was detected in all steps during the purification of NADL parti-
cles (S8 Fig). It is not clear if this difference resulted from the difference of viral strain or if E2
homodimer was contributed by the large amounts of cell-derived vesicles generated by this
cytopathic strain of BVDV. Nevertheless, the variation of homodimer:heterodimer ratio during
the purification rather suggests that homodimer and heterodimer were probably present on
different populations of objects, probably including both virions and contaminating vesicles.
Protein content of purified BVDV particles
The protein content of purified BVDV particles was analyzed by SDS-PAGE and colloidal Coo-
massie blue staining. As a control, we analyzed the protein content of an equivalent fraction
originating from non-infected MDBK cells. An intense band migrating faster than the 17-kDa
marker was present in the infected sample but not in the control (Fig 5A). The migration of
this band was similar to the one detected by immunoblot with an anti-core antibody (Fig 5B)
and to previous reports of BVDV core size [25]. The band of core appeared in less than a min-
ute after addition of the staining solution, whereas other bands began to appear after several
hours of staining, indicating that they were present in much lower amounts than core in the
sample. Core was the only protein detected by Ponceau red staining, confirming its being the
major protein present in the fraction (Fig 5B). The other bands detected in colloidal Coomassie
blue staining were far less intense and were also detected in similar amounts in the non-
infected control sample, suggesting that they are components of co-purified contaminating ves-
icles. A smeared band was detected in the infected sample, but not in the control, with a migra-
tion similar to that of Erns monomer. However, surprisingly, no band could be clearly assigned
to E1 or E2, when comparing virus and control samples, even though they were detected by
immunoblot (Fig 5B), suggesting that BVDV particles have low amounts of envelope glycopro-
teins, or that BVDV envelope glycoproteins were not efficiently stained with colloidal Coomas-
sie blue.
To further characterize the protein content of purified BVDV particles, proteins were ana-
lyzed by mass spectrometry. Proteins that were found at least twice out of 4 independent exper-
iments, including one with proteins deglycosylated by PNGase F, are mentioned in Table 1.
Two viral proteins, core and Erns, were identified, corresponding to the bands shown in Fig 5A,
but E1 and E2 were not detected using Mascot searches. The other proteins identified were
BVDV Purification
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Fig 5. Protein content of purified BVDV fraction. (A) A purified BVDV fraction and an equivalent fraction
obtained from non-infected cells (control) were analyzed by SDS-PAGE under reducing conditions and
colloidal Coomassie blue staining. Asterisk, Erns, double asterisk, core. (B) Immunoblot analysis under
BVDV Purification
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cellular proteins. They corresponded to proteins detected both in purified virus samples and in
control fractions by Coomassie blue staining, and are likely components of contaminating vesi-
cles detected in cryo-electron microscopy experiments.
To further assess the presence of E1 and E2 on purified BVDV, we compared the theoretical
tryptic digest peak list of E1 and E2 with the experimental peak lists of samples corresponding
to masses close to 25 or 55 kDa, respectively. Three masses corresponding to E2-derived pep-
tides were found in a sample of ~55 kDa containing Erns and lactadherin (S9 Fig). Due to the
low intensity of these three peaks no MSMS experiment was carried out. These data strongly
suggest the presence of E2, but do not strictly prove it. We performed a similar analysis for E1,
but could not identify it. E1 runs as a ~25 kDa protein at a position very close to that of CD9,
which is a major contaminant. We hypothesize that the presence of large amounts of CD9-der-
ived peptides could have interfered with the detection of E1-derived peptides present in low
amounts. The absence of detectable bands for E1 and E2 in Coomassie-stained gels and the
lack of detection of E1 in mass spectrometry experiments further suggest that E1E2 content of
BVDV envelope is low.
In contrast to HCV, no apolipoprotein was found associated to purified BVDV during the
mass spectrometry experiments. Among the proteins detected, major cytosolic proteins, such
as actin, tetraspanins network-associated proteins, such as CD9 and CD9P1, ESCRT proteins,
such as ALIX, and phospholipid-binding proteins, such as lactadherin and annexin A2, have
been previously found in purified exosomes from other cell types [27,28]. This suggests that
contaminants found in purified BVDV fractions are exosomes. To assess whether some of
these host factors could be virion components, we compared their distribution in a sucrose
density gradient with the distribution of E2. The bands were quantified and plotted over frac-
tion density. This revealed the presence of at least two populations of contaminating vesicles in
addition to viral particles, one enriched in annexin A2, and the other one containing CD9 and
ALIX (Fig 5C). CD9P1 and lactadherin could not be probed due to the lack of antibodies recog-
nizing bovine proteins. The buoyant density of annexin-A2 peaked at 1.108 g/cm3 while virion
marker E2 peaked at 1.127 g/cm3. The peak of the second population of contaminating vesicles
was shared by fractions with densities of 1.127 g/cm3 and 1.136 g/cm3. Despite their distinct
reducing conditions and Ponceau red staining of purified BVDV fraction. (C) Distribution of CD9, annexin A2,
ALIX and BVDV E2 in sucrose density gradient of BVDV (top) and control (bottom) fractions. Bands were
quantified by densitometry and plotted over fraction density. (D) Immunoblot analysis of annexin A2 and
BVDV core in flow through (1), PBS washes (2 and 3) and 0.4M NaCl elution (4 and 5) fractions of cellulose-
sulfate column. 1:50 of each fraction was loaded on the gel. (E) Immunoblot analysis of Annexin A2, ALIX,
CD9 and core in BVDV fractions before and after cellulose sulfate chromatography. 1:20 of input and eluted
fraction were loaded on the gel.
doi:10.1371/journal.ppat.1005476.g005
Table 1. Proteins identified bymass spectrometry in purified BVDV fractions.
Protein Origin Gene ID Nb of peptides matching MS score MSMS score/Nb of sequenced peptides
CD9P1 bovine 538209 17 76 nd
ALIX bovine 533406 15 135 150/6 peptides
lactadherin bovine 281913 14 185 51/4 peptides
Erns BVDV - 7 - 107/2 peptides
Actin bovine 280979 11 107 128/4 peptides
Annexin A2 bovine 282689 11 127 125/5 peptides
CD9 bovine 280746 5 nd 116/4 peptides
Core BVDV - 6 - 305/6 peptides
doi:10.1371/journal.ppat.1005476.t001
BVDV Purification
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distributions, CD9, ALIX and, to some extent, annexin A2 overlapped E2 in the gradient (Fig
5C).
We also assessed whether some of these host factors would preferentially co-purify with the
viral particles during the chromatography step. Cellulose-sulfate beads mimic heparan sulfate
and preferentially bind viral particles. Therefore, host factors should co-purify with virions, if
they are inserted in viral particles and should not bind beads if they are part of contaminating
vesicles. Annexin A2 was detected in fractions of a chromatography experiment. Most annexin
A2 did not bind cellulose-sulfate beads and was recovered in the flow-through fraction (Fig
5D). A minor amount of annexin A2 was detected in the 0.4 M NaCl virus elution fraction,
where core was detected. A similar analysis was performed for ALIX, and CD9 (Fig 5E). Again
most of the cellular proteins did not bind cellulose-sulfate beads, and a minor fraction was
recovered in the virus fraction. All these results strongly suggest that most of these host pro-
teins are part of contaminating vesicles, but we cannot completely rule out the possibility that a
minor fraction of some of these proteins could be associated with viral particles.
Lipid composition of purified BVDV particles
To determine if the low buoyant density of BVDV particles reflects an atypical lipid composi-
tion, as it was recently shown for hepatitis C virus particles [6], we quantified lipids of purified
viruses. In parallel, we also quantified the lipid composition of infected and non-infected
MDBK cells, in order to reveal any potential changes of lipid metabolism induced by BVDV
infection, and to estimate the enrichment or reduction of lipids in the virions. Lipids were
extracted from samples in the presence of internal lipid standards and subjected to nano-elec-
trospray ionization MS/MS analyses on a QTRAP5500. Lipid species detection was performed
in either precursor on neutral loss scanning mode, selecting for lipid class specific fragment
ions that were generated by collision-induced dissociation under high vacuum. Data evaluation
and quantitation of lipid species was done using the LipidView software. Twenty lipid classes
(13 glycerophospholipids [GPLs], 3 sphingolipids [SLs], 3 neutral lipids and cholesterol) were
included in the analysis. The GPLs analyzed were diacyl-phosphatidylcholine (PC), 1-alkyl,2-a-
cylglycerophosphocholine or 1-acyl,2-alkylglycerophosphocholine (ePC), phosphatidyletha-
nolamine (PE), 1-alkyl,2-acylglycerophosphoethanolamine or
1-acyl,2-alkylglycerophosphoethanolamine (ePE), 1-alkenyl,2-acylglycerophosphoethanola-
mine (also referred to as ethanolamine plasmalogen (pl-PE)), phosphatidylserine (PS), 1-alky-
l,2-acylglycerophosphoserine or 1-acyl,2-alkylglycerophosphoserine (ePS),
phosphatidylglycerol (PG, the mass of which is indistinguishable from its structural isomer
lyso-bisphosphatidic acid, or LBPA), 1-alkyl,2-acylglycerophosphoglycerol or 1-acyl,2-alkyl-
glycerophosphoglycerol (ePG), phosphatidylinositol (PI), 1-alkyl,2-acylglycerophosphoinositol
or 1-acyl,2-alkylglycerophosphoinositol (ePI), phosphatidic acid (PA) and 1-alkyl,2-acylglycer-
ophosphate or 1-acyl,2-alkylglycerophosphate (ePA). The three SLs analyzed were ceramide
(Cer), sphingomyelin (SM), and hexosyl-ceramide (HexCer). The three neutral lipids were
cholesteryl ester (CE), triacylglycerol (TAG) and diacylglycerol (DAG). Among the 20 lipid
classes analyzed, a total of 398 different molecular lipid species were quantified (S1 Table).
The lipidomes of BVDV particles and of total cellular membranes revealed a ~2.3 to 3.5 fold
enrichment of cholesterol, SM and HexCer in the viral envelope as compared to cellular mem-
branes (Table 2 and Fig 6). Cholesterol and SM account for 51 and 17 mol% of BVDV lipids,
respectively. Together with HexCer, they contribute to more than 70 mol% of envelope lipids,
while their abundance in MDBK cellular membranes is close to 30 mol%. This enrichment in
cholesterol and SLs is mirrored by a 1.5 to 5 fold reduction of all GPL classes. In contrast, the
lipid composition of infected and non-infected MDBK cells did not reveal any significant
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differences. Storage lipids CE, DAG and TAG were found in similar amounts in purified virus
and in a control fraction obtained from non-infected cells. Therefore, they most likely repre-
sent components of contaminating material (S10 Fig). The same conclusion applies to Cer and
PG, which were also measured in similar amounts in purified virus and control fractions.
In addition to the differences observed for lipid classes, some differences could also be
observed between individual lipid species of BVDV envelope and MDBK membranes. There is
a tendency toward more saturated PC species in BVDV samples as compared to MDBK cells.
PC species containing 0, 1 or 2 double bonds in acyl chains make up 82.5% of all PC species of
BVDV and about 55% in MDBK cells (Fig 7A). Additionally, there is a shift toward shorter
acyl chains. PCs with a sum of 34 carbon atoms in acyl chains were relatively more abundant
in BVDV than in MDBK cells, at the expense of species with a sum of 36 carbon atoms or more
in acyl chains (Fig 7B). As a result, PC 34:2 and PC 36:2, the major PC species represent 46.8%
of all PC species in BVDV and 30.2% or 31.3% in infected and non-infected MDBK cells,
respectively (Fig 7C). The tendency towards less unsaturated acyl chains is conserved, although
less pronounced in PE and PI but not in other major GPL classes or in SLs (S11 Fig).
We also compared BVDV lipid content with other viruses [6,29–31]. Strikingly, BVDV was
most similar to influenza virus, when the repartition of major lipid families such as cholesterol,
SLs and GPLs, are compared. The distribution of major lipid families of its envelope was very
different from that of HCV, another member of the Flaviviridae family, essentially because CE
Table 2. Lipid class composition of infected and non-infected MDBK cells and BVDV produced in MDBK cells.
Lipid Avg mol% ± SD*
MDBK cells BVDV**
Infected Non-infected
PC 27.87 ± 1.45 28.92 ± 4.81 15.80 ± 1.35
ePC 3.06 ± 0.71 3.07 ± 0.92 1.73 ± 0.34
PS 5.69 ± 0.27 4.74 ± 1.26 0.95 ± 1.31
ePS 0.22 ± 0.02 0.17 ± 0.05 0.03 ± 0.01
PE 16.90 ± 2.44 15.95 ± 2.31 5.39 ± 2.47
ePE 1.09 ± 0.13 1.03 ± 0.14 0.23 ± 0.24
pl-PE 5.43 ± 0.64 6.68 ± 0.87 3,56 ± 1.06
PG 0.12 ± 0.02 0.11 ± 0.03 0.01 ± 0.01
ePG 0.02 ± 0.00 0.02 ± 0.00 NA***
PI 4.68 ± 0.85 3.73 ± 1.10 1.52 ± 0.33
ePI 0.19 ± 0.01 0.14 ± 0.01 0.01 ± 0.01
PA 0.30 ± 0.12 0.31 ± 0.09 0.02 ± 0.00
ePA 0.01 ± 0.01 0.01 ± 0.01 NA
Cer 0.23 ± 0.10 0.21 ± 0.14 NA
SM 6.81 ± 0.12 6.88 ± 0.68 16.74 ± 2.54
HexCer 0.85 ± 0.24 0.84 ± 0.37 2.96 ± 0.81
Chol 22.47 ± 4.24 23.88 ± 0.93 51.02 ± 1.99
CE 1.59 ± 1.24 1.05 ± 0.61 NA
DAG 1.22 ± 0.38 1.03 ± 0.54 0.02± 0.04
TAG 1.25 ± 0.53 1.23 ± 0.67 NA
*3 independent experiments
** lipids measured in non-infected control preparations were subtracted
***NA, not available (same amounts in control and BVDV preparations)
doi:10.1371/journal.ppat.1005476.t002
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is the major lipid found in HCV [6] and is most probably absent from BVDV. Even when the
storage lipid CE was omitted, BVDV and HCV distributions were still dissimilar, BVDV
(51.0% Chol, 29.3% GPLs) being much closer to influenza (52.3% Chol, 29.1% GPLs) [31] than
to HCV (37.2% Chol, 43.3% GPLs) [6], VSV (43.6% Chol, 36.9% GPLs), SFV (42.7% Chol,
37.2% GPLs) [30] or HIV (45.2% Chol, 36.4% GPLs) [29] (Fig 8A). All viruses had similar SLs
content (18.5 to 20%).
Remarkably, when GPLs distributions were compared, BVDV and influenza were very dif-
ferent from each other. The major GPL of BVDV was PC (61.6% of all major GPLs), which is
the main GPL found in the ER membrane [32]. In contrast, PC was detected in very small
amounts (6.4%) in influenza virus [31]. Influenza virus envelope was enriched in ePE and PS
(31.3 and 43%, respectively), while they represent only 0.9% and 3.8% of BVDV envelope GPLs
(Fig 8B). In this respect, BVDV GPL content is closer, although clearly different, to that of
HCV [6], another virus probably budding at the ER membrane, than to any other virus
included in this analysis.
Importance of sphingomyelin and cholesterol in BVDV infection
To assess the functional importance of sphingomyelin and cholesterol, the two major lipids
enriched in BVDV virions, we made use of sphingomyelinase and methyl-β-cyclodextrin,
Fig 6. Lipid class composition of BVDV and MDBK cells. The content of individual lipid classes of infected MDBK cells, non-infected MDBK cells and
purified BVDV were standardized to mole percentage of all membrane lipids within the sample. Amounts of lipids measured in control preparation from
uninfected cells were subtracted from BVDV lipid values. Glycerophospholipids (GPL): phosphatidic acid (PA), phosphatidylcholine/-ethanolamine/-glycerol/-
inositol/-serine (PC/PE/PG/PI/PS), ether linked GPL (ePC/ePE/ePG/ePI/ePS/ePA), and ethanolamine plasmalogen (pl-PE). Sphingolipids (SL): ceramide
(Cer), sphingomyelin (SM) and hexosylceramide (HexCer). Sterols: cholesterol (Chol). Storage neutral lipids: cholesteryl esters (CE), diacylglycerol (DAG)
and triacylglycerol (TAG). Error bars correspond to SDs (n = 3).
doi:10.1371/journal.ppat.1005476.g006
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Fig 7. Phosphatidylcholine species of BVDV and MDBK cells. (A) PC saturation as a number of double bonds in both fatty acyl chains. (B) PC chain
length as number of carbon atoms in both fatty acyl chains. (C) Molecular PC species. Amounts of each lipid were standardized to the total identified PC
species. Error bars correspond to SDs (n = 3).
doi:10.1371/journal.ppat.1005476.g007
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respectively. BVDV was pre-incubated with increasing amounts of sphingomyelinase (up to 10
U/ml), and then diluted in culture medium before infection of MDBK cells. A dose-dependent
inhibition of BVDV infection was observed (Fig 9A). To ensure that this inhibition did not
result from an action of sphingomyelinase on MDBK cells, a control experiment was per-
formed with no pre-incubation with the virus before dilution and infection, and no inhibition
of BVDV infection was detected (panel A in S12 Fig). Alternatively, cells were pre-treated with
diluted sphingomyelinase in the absence of virus and then infected in the absence of sphingo-
myelinase, or infected in the absence of sphingomyelinase and then treated with diluted sphin-
gomyelinase post infection. Again no impact on BVDV infection was measured with these
conditions (panel A in S12 Fig). These results indicate that lipid modifications induced in
BVDV envelope by sphingomyelinase treatment impaired BVDV infection.
BVDV was also treated with increasing concentrations of methyl-β-cyclodextrin, in order to
extract cholesterol from its envelope, and then diluted before infection of MDBK cells. Again, a
dose-dependent inhibition of BVDV infection was observed (Fig 9B). Control experiments
with no pre-incubation did not show any inhibition of BVDV infection (panel B in S12 Fig),
indicating an action of methyl-β-cyclodextrin on viral particles and not on cells. Importantly,
when BVDV treated with 2.5 mg/ml methyl-β-cyclodextrin was further incubated with choles-
terol-loaded methyl-β-cyclodextrin before infection of MDBK cells, in order to replenish the
cholesterol content of the viral envelope, the infectivity was partially restored (Fig 9C). In con-
trast, BVDV treated with 5 mg/ml methyl-β-cyclodextrin could not be rescued by cholesterol
addition. This suggests that a strong cholesterol extraction from the viral envelope irreversibly
inactivates the virus, whereas a partial cholesterol extraction impairs BVDV infection but does
not irreversibly disrupt the viral envelope.
Fig 8. Lipid compositions of viruses. (A) Major lipid categories and (B) glycerophospholipid class compositions of influenza virus (IFV, ref #30), vesicular
stomatitis virus (VSV), Semliki forest virus (SFV) (both taken from ref #29), human immunodeficiency virus (HIV, ref #28), hepatitis C virus (HCV, ref #6) and
BVDV (this study). GPL: glycerophospholipid, SL: sphingolipid, chol: cholesterol, PI: phosphatidylinositol, PS phosphatidylserine, PE:
phosphatidylethanolamine, PC: phosphatidylcholine, ePE: ether-linked PE, ePC: ether-linked PC. Cholesteryl esters of HCV have been omitted to facilitate
the comparison with other viruses.
doi:10.1371/journal.ppat.1005476.g008
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Examination of BVDV by cryo-EM confirmed the integrity of virions in samples treated
with 1 U/ml sphingomyelinase or 2.5 mg/ml methyl-β-cyclodextrin (S13 Fig). This indicates
that the loss of infectivity is not due to the viral particles being destroyed and indeed results
from the depletion of specific lipids from the envelope. In contrast, the sample treated with 5
mg/ml methyl-β-cyclodextrin, which did not allow infection rescue by cholesterol replenish-
ment (Fig 9C), contained no virus (S13 Fig). Only a few non-viral intact vesicles, probably
derived from cholesterol-poor contaminating membranes, and a number of large aggregates
containing membranous material were observed (S14 Fig). This observation explains the lack
of cholesterol-mediated rescue with this dose of methyl-β-cyclodextrin. These results con-
firmed the functional importance of sphingomyelin and cholesterol in BVDV entry.
Assessment of the role of lipid rafts for BVDV assembly
The lipid composition of BVDV envelope suggests that it might bud in membrane domains
enriched in cholesterol and SM. Membranes enriched in cholesterol and sphingolipids have a
tendency to produce lipid raft domains [33]. These structures are thought to be insoluble and
coalesce in cold non-ionic detergents and can be isolated by flotation in a sucrose density gradi-
ent as proteo-lipidic complexes named detergent-resistant membranes, or DRMs [34]. To
determine if BVDV envelope glycoproteins can be found in DRMs, BVDV-infected cells were
lysed on ice in TNE containing Triton X-100 and the lysate was submitted to flotation in a
sucrose density gradient in order to resolve DRMs from soluble proteins. Most of caveolin (a
DRMmarker) was found in floated fractions, whereas the transferrin receptor (a protein
excluded from DRMs) was not (Fig 10A). We also probed the distribution of calnexin, a trans-
membrane protein of the ER, and did not observe any signal in floated fractions, as expected,
indicating that the ER membrane was well solubilized. Under these experimental conditions,
E2 was not found in DRM fractions from infected cells lysates (Fig 10A) and in floated frac-
tions from BVDV particles lysates (Fig 10B). This indicates that, despite a high cholesterol and
Fig 9. Sphingomyelin and cholesterol in BVDV entry. (A) Unpurified BVDV was incubated for 1h at 37°C in the presence of indicated concentrations of
sphingomyelinase (SMase), diluted 1,000 times and used to infect MDBK cells. (B) Partially purified BVDV was incubated at 37°C for 1 h with indicated
concentrations of methyl-β-cyclodextrin (MBCD), diluted 10,000 times and used to infect MDBK cells. (C) Partially purified BVDV was incubated at 37°C for 1
h with indicated concentrations of MBCD (incubation 1), diluted 100 times, incubated for 1h at 37°C with MBCD:cholesterol complex at final cholesterol
concentrations indicated (incubation 2), diluted 100 times and used to infect MDBK cells. The number of infected cells was measured using an
immunofluorescence assay at 15 hpi and standardized to the number of cells infected with untreated virus. Error bars correspond to SDs (n = 3, * P<0.05,
*** P<0.001, NS: P>0.05; cholesterol-treated vs corresponding control, 2-way ANOVA).
doi:10.1371/journal.ppat.1005476.g009
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SM content of BVDV envelope, E2 does not appear to be included in raft-like structures of the
ER membrane or the viral envelope.
Discussion
Purification of BVDV particles
In this study, we report on the first purification of BVDV particles and the description of their
morphology and their molecular composition. Due to moderate viral titers and to the presence
of contaminating vesicular material of cellular origin, the four-step purification we set up yields
a virus ~90% pure (Fig 1 and Fig 2). The contaminating material included two distinct vesicle
populations with different buoyant densities and protein content (Fig 5). One of these vesicle
populations with a density of about 1.14 g/cm3 and containing exosome markers such as the
tetraspanin CD9 and the ESCRT protein ALIX can be identified as exosomes originating from
intraluminal vesicles of multivesicular bodies [27,28]. The other population, which is lighter
and contains annexin A2, might have another cellular origin. Importantly, both of these cell-
derived vesicle populations are also present in conditioned medium of non-infected MDBK
cells, clearly indicating that they are unrelated to BVDV infection and viral morphogenesis.
Nevertheless, the presence of limited amounts of contaminating vesicles did not impede mor-
phological and biochemical studies of BVDV particles. One key issue to achieve this purifica-
tion was the use of a non-cytopathic strain in order to minimize the amounts of contaminating
material in supernatants of infected cells. For this reason, attempts to purify BVDV particles
from the cytopathic strain NADL were unsuccessful (S6 Fig), despite higher titers.
Morphology of BVDV particles
Purified BVDV virions appeared in electron microscopy as spherical particles with a diameter
of 50 nm (Fig 2), in keeping with previous observations of cell-associated BVDV particles
[16,23]. In cryo-electron microscopy, virions are characterized by an electron-dense core
Fig 10. E2 is excluded from detergent-resistant membranes. DRMs were isolated by cold extraction of
BVDV-infected MDBK cells (A) or partially purified BVDV (B) with Triton-X100 and flotation as explained in
the Materials and Methods section. The distribution of BVDV E2, calnexin(CNX), transferrin receptor (TFR)
and caveolin (CAV) was determined by immunoblot under reducing (CNX, TFR) or non-reducing (E2, CAV)
conditions.
doi:10.1371/journal.ppat.1005476.g010
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surrounded by a lipid bilayer, which displays a smooth surface with no spikes (Fig 2 and S1
Fig). This could reflect the presence of envelope glycoproteins lying parallel to the lipid bilayer,
like E dimers of flavivirus mature virions [3,35]. However, acidic treatment of purified BVDV
virions did not induce the formation of spikes (S7 Fig), in contrast to what has been reported
for flaviviruses [36]. This difference of response to an acidic treatment may result from the pH-
insensitivity of BVDV [22], or the structural organization of BVDV envelope glycoprotein E2,
which is very different from class II glycoprotein E of flaviviruses [10,11]. Alternatively, this
may also reflect the presence of low amounts of envelope glycoproteins at the surface of BVDV
particles, a hypothesis that is also supported by biochemical data (Fig 5 and S9 Fig).
Interestingly, the vast majority of viral particles observed in cryo-electron microscopy have
a uniform size of approximately 50 nm, except for a low number (about 2%) that are larger
with a diameter up to 65 nm (Fig 2 and S1 Fig), which corresponds to a volume twice as large.
We cannot exclude that these larger particles could be aberrant forms related to cell culture
conditions. However, BVDV is known to be able to incorporate pieces of host RNA into its
genome [14]. We can speculate that a size flexibility of the virion would be an advantage for
the virus to accommodate larger genomes. To our knowledge, such a size flexibility of the
virion has not been observed for flaviviruses. This suggests different structural organization of
the capsid of pestiviruses and flaviviruses. The polymorphic nature of a viral particle may arise
from non-icosahedral structure, as in rubella virus [37], or from variations in quasi-symmetry
or triangulation number of icosahedral structure, as in hepatitis B virus capsid [38]. Whether
BVDV capsid structure is isosahedral or not must await studies with higher resolution cryo-
EM techniques.
The purified virus preparation also contained non-enveloped particles corresponding to
putative naked capsids (Fig 2 and S1 Fig). This is most likely an artifact of the last step of purifi-
cation, for two reasons: non-lipidated particles, if infected cells were to secrete them, should
have a buoyant density quite different from that of enveloped particles and be discarded during
the two steps of ultracentrifugation. However we always detected a single peak of capsid-con-
taining material in these two ultracentrifugation steps. Moreover, cryo-electron microscopy
examination of virus fractions obtained after the flotation gradient but without chromatogra-
phy on sepharose-sulfate beads did not reveal any naked capsid-like particle. This strongly sug-
gests that non-enveloped capsids are generated during the last step of purification.
Protein content of BVDV particles
One surprising finding of this study is the apparent low glycoprotein content of BVDV parti-
cles. E1 and E2 were never detected in colloidal Coomassie blue-stained gels, while core was
very abundant and even some proteins of the ~10% contaminating material were easily
detected (Fig 5). On the other hand, Erns was detected as a smear, however apparently in lower
amounts than core (Fig 5). This suggests that BVDV particles have a higher content of Erns
than E1 and E2, a conclusion that is also supported by results of mass spectrometry analysis.
E1 was not detected in four independent experiments, and E2 could be identified only in low
amounts (S9 Fig), while Erns could easily be identified. The deglycosylation of viral particles
with PNGase did not improve E1 and E2 detection in mass spectrometry (Table 1), suggesting
that their low levels of detection did not simply result from hindrance caused by their carbohy-
drate moieties. These lower amounts of E1 and E2 were previously suggested from immuno-
gold labeling of BVDV particles in electron microscopy [15]. Lower levels of E1E2 are
surprising because E1 and E2 are required for pestivirus entry and Erns is not [39,40]. However,
we should keep in mind that it has been reported for other viruses that a very low number of
functional envelope proteins may be required for entry [41–44].
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E1 and E2 could be detected in purified BVDV particles by immunoblotting (Fig 1, Fig 4
and Fig 5), by neutralization (S4 Fig) and by immunocapture (Fig 3). As reported earlier
[23,45], E1 and E2 were found as covalent heterodimers. In contrast, cell lysates of infected
cells showed a mixture of monomers, covalent heterodimers and covalent E2 homodimers (Fig
4). This suggests that a mechanism operates during morphogenesis that allows covalent hetero-
dimers to be specifically incorporated in the nascent particle. Alternatively, E1 and E2 disulfide
bridges could be reshuffled during assembly. The presence of covalent heterodimers is consis-
tent with the report that only covalent E1E2 heterodimers are required for BVDV entry, and
that covalent E2 homodimers are inactive [40]. In previous studies, E2 covalent homodimers
were detected in unpurified pestivirus particles in addition to covalent E1E2 heterodimers [23–
25]. It is not yet clear whether the presence of E2 homodimers in virions is strain-specific, or if
it merely reflects the presence of contaminating vesicles of cellular origin. For example, mate-
rial secreted by MDBK cells infected by cytopathic strain NADL contained both homodimers
and heterodimers. Although we did not succeed in purifying NADL particles, we observed that
the homodimer:heterodimer ratio varied during purification (S8 Fig), suggesting that they are
present in different populations of vesicles in the starting material.
Lipid content of BVDV particles
Amajor finding of this study is the unexpected lipid composition of BVDV envelope (Fig 6,
Fig 7 and Table 2). The lipid composition of the viral envelope does not match any known
intracellular membrane. Its cholesterol and SM content are somewhat similar to what could be
found in the plasma membrane of some cells, and in envelopes of viruses budding at the cell
surface (Fig 8). However PS and ethanolamine plasmalogens, two phospholipids enriched in
the plasma membrane and viruses budding at the plasma membrane [29–31,46] were found in
low amounts in BVDV envelope, suggesting that the lipid bilayer of the viral envelope is not
likely to derive from the plasma membrane. Similarly, the very low ceramide and PG/LBPA
content of BVDV envelope does not support a budding event in multivesicular endosomes. A
high content of cholesterol and sphingolipids is often associated with lipid rafts [33]. However,
ethanolamine plasmalogens, another marker of lipid rafts [47], are not enriched in BVDV
envelope (Fig 6 and Table 2). Moreover, viral glycoprotein E2 was not found in DRMs of
infected cells or purified virus (Fig 10). These observations are not in favor of BVDV budding
in lipid raft microdomains of MDBK cells.
Several lines of evidence are in favor of BVDV budding into the ER. Envelope glycoproteins
are located at the ER membrane of infected cells [48,49]. Infectious BVDV particles accumulate
intracellularly upon brefeldin A treatment [50]. Individual budding events at the ER membrane
have been observed by electron microscopy [16]. In contrast, the BVDV envelope lipid compo-
sition, and especially its cholesterol and SM content, is quite different from a typical ER mem-
brane [32,51], even though the lipid content of the ER of MDBK cells has not been determined
to our knowledge. Interestingly, SM has been recently shown to be involved in the morphogen-
esis of West Nile virus [52], a flavivirus that also buds in the ER, suggesting a potential role of
SM in viral budding in the ER. On the other hand, if one only considers GPLs, it is worth not-
ing that BVDV envelope is quite similar to ER membrane [32,51] and to the envelope of HCV,
another virus budding in the ER [6], which both contain high amounts of PC and PE (Fig 8).
These data suggest that the distribution of GPLs could be more representative of the membrane
where the virus buds than the full lipid repertoire.
Remarkably, BVDV and influenza virus, two viruses budding from cellular membranes so
different as ER and apical PM, reach similar proportions of GPLs, SLs and cholesterol (Fig 8).
Their high cholesterol and SLs contents are likely to render their envelopes very sturdy and
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help them to resist to harsh conditions found outside their hosts. It is tempting to hypothesize
that this is an example of convergent evolution driven by similar modes of transmission. Influ-
enza lipid content is very similar to apical PM content and the formation of its envelope only
involves minor sorting events of selected lipid species [31]. On the other hand, BVDV envelope
lipid content is highly divergent from a typical ER membrane composition. Three different
hypotheses could explain this observation. A first hypothesis is that the viral infection could
alter the cellular metabolism in such a way as to modify the lipid composition of the cellular
membrane where the virus buds, here the ER membrane. However this hypothesis is unlikely,
because we did not detect any difference of lipid content between infected and non-infected
cells (Table 2). Actually, BVDV replication has been associated to very discrete membrane
rearrangements [53]. This absence of any major membrane rearrangement is in line with the
absence of lipid content modification during BVDV infection. A second hypothesis is that
BVDV would bud into microdomains of the ER membrane enriched in cholesterol and SM,
whether they are normally present in the ER membrane or their formation is induced during
BVDV infection. Although ER is known not to be enriched in SM and cholesterol, evidence for
the presence of DRMs in the ER has been reported [54,55], suggesting a mosaic composition of
the ER membrane. However, our results do not support BVDV budding in lipid rafts (Table 2
and Fig 10). Alternatively, a third hypothesis is that viral proteins could recruit/concentrate
cholesterol and sphingolipids to nascent viral envelope during the budding process. It is
unlikely that E2 could drive such a process, because of its low amounts in virions and its low
affinity to membranes enriched in cholesterol and SLs. Viral proteins fitted for performing
such a function might be core, Erns and/or non-structural proteins involved in the assembly
process, such as NS3 [17].
Our data add to the notion that members of different genera of the Flaviviridae family use
different mechanisms for their morphogenesis. Unlike flaviviruses, HCV [6,7] and BVDV (this
work) appear to contain a limited number of envelope glycoproteins per virion. BVDV also dif-
fers from HCV, which uses the machinery of VLDL formation of hepatocytes [4]. The absence
of associated apolipoproteins and the very low amounts of CE and TAG, if any, in BVDV parti-
cles clearly indicates that BVDV does not rely on lipoproteins for its morphogenesis, in agree-
ment with previous demonstration that LDL receptor plays no role during BVDV entry [56].
Our results further suggest that major changes of lipid content in the bilayer originating from
the ER membrane are involved in the formation of BVDV envelope. Future studies on molecu-
lar and cellular mechanisms operating this process of lipid sorting should indicate important
aspects of pestivirus morphogenesis.
Materials and Methods
Chemicals
Dulbecco’s modified Eagle’s medium (DMEM), phosphate buffered saline (PBS), glutamax,
horse and goat sera, DAPI, gentamycine, nonessential amino acids and trypsin/EDTA were
purchased from Life Technologies. All other chemicals were purchased from Sigma.
Cell culture
BVDV-free MDBK cells (ATCC number CCL-22) were propagated in DMEM, high glucose
modification, supplemented with 10% heat-inactivated horse serum, nonessential amino acids
and 2 mM glutamax at 37°C in a humidified atmosphere containing 5% CO2, and were pas-
saged by trypsination twice a week.
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Virus
BVDV genotype 1 non-cytopathic strain WAX-N used in this study was obtained from P.P.
Pastoret (University of Liège, Belgium), and maintained by passages in MDBK cells. The cod-
ing sequence of the N-terminal part of the polyprotein (Npro-p7), which encompasses the
structural proteins, was determined from RT-PCR fragments amplified from total RNA of
infected cells using primers listed in table A in S1 Text, and deposited to Genebank (accession
number KR013753).
BVDV cytopathic strain NADL was obtained from C. M. Rice (The Rockefeller University,
New York).
Virus titration
About 104 MDBK cells were seeded in wells of P96 plates and infected 4 hours later with
10-fold dilution series of BVDV samples. The medium was replaced after 1 hour of contact.
Cells were fixed at 18 to 20 hpi with 3% paraformaldehyde and processed for immunofluores-
cent detection of NS3. Immunofluorescent foci were counted from wells infected with appro-
priate BVDV dilution, and viral titers were expressed as focus-forming units (ffu) per ml.
Antibodies
Anti-BVDV core polyclonal antibody. The core-coding sequence of BVDV strain NADL
was PCR-amplified from pACNR-BVD NADL [57], subcloned into pGEX-4T1 and a GST-
core fusion protein was produced in E. coli BL21 (DE3). Polyclonal anti-BVDV core antiserum
was prepared by immunizing a rabbit with affinity-purified GST-core. Anti-core IgG were
affinity-purified from immune serum. To this end, a His6-tagged version of BVDV core was
expressed in E. coli BL21 (DE3), purified by affinity chromatography (Ni-NTA superflow car-
tridges, Qiagen), and coupled to CNBr-activated sepharose-4B. The IgG fraction of the
immune serum was recovered by fractionated ammonium sulfate precipitation, and run
through the His6-core-sepharose 4B affinity column. Bound IgG was eluted with 4 MMgCl2,
10 mMNa2PO4, pH 7.4 and dialyzed against PBS (PBS is 137 mMNaCl, 2.7 mM KCl, 1.2 mM
KH2PO4, 8.1 mMNa2HPO4, pH 7.0).
Generation of BVDV E1 monoclonal antibody. In a first step, a PCR fragment containing
murine ubiquitin (ubiN: TTTCATATGCAGATCTTCGTGAAG; ubiC: AAAGGATCCG
CCACCGCGGAGTCGCAGCAC) was generated and cloned into the NdeI-BamHI sites of
pET26b. Next, the ectodomain of E1 of BVDVNCP-7 was amplified with oligonucleotides
BVTK94 (AAAGATCTGCCCTTCTCCCTATTGTGAGG) and BVTK121 (TCTCGAAG
ATCTGGTCTTACACAAAC) complementary to nt 1877–1892 and nt 2236–2254, respectively
of BVDVNCP7) and cloned via EcoRI and XhoI between the ubiquitin gene and the hexa His
tag, yielding plasmid pTK232. The ubiquitin-E1 6xHis protein was expressed in Rosetta DE3
cells at 30°C for 4h after induction with 1mM IPTG. The insoluble protein was solubilized using
6M guanidium hydrochloride (Sigma) and purified by chromatography on HisTrap columns
(GE healthcare) [58]. 0.5mg of purified protein was desalted and served for immunization of 2
BalbC/black mice after adding Gerbu Adjuvant MM as recommended by the manufacturer
(Gerbu, Heidelberg). Mice were immunized a total of 6 times before spleenocytes were fused
with SP2/0 cells as described [58]. Hybridomas were screened using the ubi-E1 fusion protein or
an unrelated ubiquitin fusion protein for differentiation by ELISA. A single hybridoma (8F2) was
recovered that detected the E1 moiety in ELISA, Western blot and immunofluorescence.
Other antibodies. The mouse mAb OSC-23 to BVDV NS3 protein [59] was kindly pro-
vided by P.P. Pastoret (University of Liège, Belgium) and G. Chappuis (Merial company,
France). MAb OSC-23 was used as unpurified culture medium from hybridoma grown in a
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miniperm apparatus (Heraeus). Rabbit polyclonal anti-Erns was kindly provided by Gregor
Meyers, Friedrich-Loeffler-Institut, Greifswald—Insel Riems, Germany. Mouse mAbs anti-
BVDV E2WB166 and WB214 were obtained from Veterinary Laboratories Agency, Addel-
stone, UK. Anti-bovine CD9 mouse mAb IVA50 was from Novus. Anti-annexin A2 mouse
mAb was from Life Technologies. Anti-KDEL mouse mAb (used as irrelevant in immunocap-
ture experiments) was from Stressgen. Anti-calnexin rabbit pAb was from Enzo Life Sciences.
Anti-transferrin receptor mouse mAb H68.4 was from Santa Cruz Biotechnology. Anti-caveo-
lin rabbit pAb was from Transduction Laboratories.
Purification of BVDV particles
Approximately 3.108 MDBK cells were infected in suspension with occasional mixing at an M.
O.I. of approximately 0.02 for 1 hour at room temperature in a volume of 20 ml DMEM con-
taining 10% horse serum and then diluted to 450 ml of DMEM containing 2% horse serum
and plated in 3 cell factories (Easyfill-2trays, Nunc). Cell culture supernatants were collected at
40 hpi and then again 24 h later. Both cell culture supernatants were combined and centrifuged
at 5000 rpm, 4°C for 15 minutes in a JS-7.500 rotor (Beckman) to get rid of cellular debris.
Polyethyleneglycol (PEG)-6000 (7%) was slowly added to supernatants under stirring in order
to allow rapid solubilization. The mixture was incubated at 4°C under slow continuous stirring
for 4 hours and centrifuged at 10,000 rpm, 4°C for 30 minutes in a JLA-10.500 rotor (Beck-
man). The pellet was resuspended in 7 ml TNE (TNE is 20 mM TrisCl pH 8.0, 150 mMNaCl,
2 mM EDTA) and incubated overnight at 4°C. Insoluble material was removed by centrifuga-
tion (7000 rpm, 4°C for 10 minutes in a JS-7.500 rotor). The supernatant was loaded over 2 lay-
ers of 30% (2ml) and 15% (3 ml) sucrose (w:v) in TNE in a 12-ml ultraclear centrifuge tube
(Beckman) and centrifuged at 35,000 rpm, 4°C for 2 hours in an SW 41 rotor (Beckman). Frac-
tions (0.5 ml) were collected dropwise after puncturing the bottom of the tube. The fraction
containing the major part of infectious virus and core protein was mixed with 1 volume of 60%
sucrose in TNE, loaded under a 5–35% sucrose gradient, and centrifuged at 35,000 rpm, 4°C
for 20 hours in an SW 41 rotor. Fractions (0.5 ml) were collected dropwise after puncturing the
bottom of the tube. The distribution of the virus in the gradient was measured by titration and/
or core immunoblotting. The density of each fraction was measured with a refractometer. One
or two fractions of the gradient containing the peak of infectious virus were loaded on a 0.5-ml
column of sulfated cellulose (Cellufine Sulfate, Chisso Corporation) pre-equilibrated with
TNE. After virus binding, the column was washed with 3 volumes of PBS and viral particles
were eluted in 1 ml of PBS containing 0.4 M NaCl. Eluted fraction was centrifuged at 45,000
rpm, 4°C for 3 hours in a TLA-55 rotor (Beckman) and the pellet of purified virus was resus-
pended in 50 μl PBS. For electron microscopy analysis, the virus was kept at 4°C in PBS until
analysis. For lipid extraction and analysis, two preparations were pooled. The final pellet was
resuspended in 155 mM ammonium bicarbonate and kept at -80°C.
Cryo-electron microscopy
Firstly a continuous carbon film was deposited on the carbon face of a quantifoil with circular
holes cupper grid (Ted Pella Inc). BVDV samples (5 μl) were deposited onto the cupper surface
of the grid placed in the automated device for plunge-freezing (EM GP Leica) enabling a per-
fect control of temperature (15°C) and relative humidity (70% RH). The excess of sample was
blotted with filter paper and the grid was plunged into a liquid ethane bath cooled and main-
tained at -183°C with liquid nitrogen. Specimens were maintained at a temperature of approxi-
mately -170°C, using a cryo holder (Gatan, CA, USA) and observed with a FEI Tecnai F20
electron microscope operating at 200 kV and at a nominal magnification of 29,000 x under
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low-dose conditions. Images were recorded with a 2k x 2k USC 1000 slow-scan CCD camera
(Gatan). Pixel size was 0.37 nm.
Immunocapture of BVDV particles using magnetic beads
Protein A and protein G-conjugated superparamagnetic beads (Bio-Adembeads) were pur-
chased from Ademtech. Before use, the beads were washed with a large volume of working
buffer (PBS). The magnetic beads (10 μl) were incubated with anti-BVDV E2 mAb or anti-
KDEL mAb (control) in a final volume of 200 μl, at 4°C for 30 min. The magnetic bead–protein
A/G–antibody complexes were sedimented with a magnet. The pellets were washed three times
to remove excess antibody. Beads coated with antibody were incubated with BVDV at room
temperature for 30 min (final volume 100 μl). After sedimentation with the magnet, the pellet
was washed in order to remove unbound particles. Cryo-TEM lacey carbon cupper grids were
then prepared with this suspension, without any further treatment according to the protocol
described above. Specimens were maintained at a temperature of approximately -170°C, using
a cryo holder (Gatan, CA, USA) and observed with a FEI Tecnai12 electron microscope operat-
ing at 120 kV and at a nominal magnification of 30,000 x under low-dose conditions. Images
were recorded with a 4k x 4k slow-scan CCD camera (FEI).
Protein identification by mass spectrometry
Proteins of purified virus or a corresponding fraction from non-infected cells were separated
under reducing conditions in a 12% polyacrylamide gel. In one experiment, half of a purified
virus preparation was denatured and deglycosylated overnight at 37°C with PNGase F (P0704,
New England Biolab) as recommended by the manufacturer, before gel electrophoresis. The
gel was stained for 3 days in a solution of colloidal Coomassie blue. Stained bands were excised
from the gel, reduced, alkylated with iodoacetamide (10 mg/ml in NH4HCO3 20 mM) and
digested overnight with 50 ng trypsin (Promega) in 20 mMNH4HCO3. The resulting peptides
mixtures were eluted from the gel, desalted, and spotted on a MALDI plate with freshly dis-
solved α-cyano-4-hydroxycinnaminic acid (10 mg/ml in 50% CH3CN, TFA 1/1000). Mass
spectrometry was performed with a MALDI-TOF-TOF Autoflex Speed (Bruker Daltonics).
MS and MS/MS data were analyzed using BioTools software. Identification of peptides was
performed using Mascot, http://www.matrixscience.com/.
Lipid extraction and mass spectrometry
Lipid extractions were performed using chloroform:methanol:37% HCl (5:10:0.15, vol:vol:vol,)
except for plasmalogens, which were extracted using chloroform/methanol (5:10, vol:vol) as
extraction solvent. Lipid extractions were done in 10 ml Wheaton vial with Teflon-screw caps
as described [60]. Typically, the following lipid standards were added to the solvent prior to
extractions: 100 pmol of PC (13:0/13:0, 14:0/14:0, 20:0/20:0; 21:0/21:0, Avanti Polar Lipids),
SM (d18:1 with N-acylated 15:0, 17:0, 25:0, semi-synthesized as described in [36]) and d6Chol
(Cambrigde Isotope Laboratory), 55 pmol PI (16:0/16:0, 17:0/20:4, Avanti Polar Lipids),
50 pmol PE and PS (14:1/14:1, 20:1/20:1, 22:1/22:1, semi-synthesized as described in [60],
DAG (17:0/17:0, Larodan) and cholesterol ester (CE, 9:0, 19:0, 24:1, Sigma), 40 pmol TAG
(D5-TAG-Mix, LM-6000 / D5-TAG 17:0,17:1,17:1 –Avanti Polar Lipids), 10 pmol Cer and
GlcCer (d18:1 with N-acylated 15:0, 17:0, 25:0, semi-synthesized as described [60], PA (PA
17:0/20:4, Avanti Polar Lipids) and PG (14:1/14:1, 20:1/20:1, 22:1/22:1, semi-synthesized as
described in [60]. Neutral extraction solvents were spiked with 100 pmol PC standard mix and
plasmalogen PE (pl-PE) standard mix containing 66 pmol pl-PE Mix 1 (16:0p/15:0, 16:0p/19:0,
16:0p/25:0), 93 pmol pl-PE Mix 2 (18:0p/15:0, 18:0p/19:0, 18:0p/25:0) and 129 pmol pl-PE Mix
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3 (18:1p/15:0, 18:1p/19:0, 18:1p/25:0). Semi-synthesis of pl-PE was performed as described in
[61]. For lipid analysis, 10–20 μl of purified virions and 1-5x104 cells were subjected to extrac-
tions. Mass spectrometric analysis was performed on a QTRAP5500 (ABSciex) coupled to a
Triversa NanoMate device (Advion) as described [60]. Data processing was performed using
LipidView (ABSciex), Microsoft Excel and a custom-made data evaluation program
(ShinyLipids).
Immunoblotting
Cells were incubated in lysis buffer (50 mM Tris-Cl buffer pH 7.5 containing 100 mMNaCl, 1
mM EDTA, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), and protease inhibitors) for
20 min on ice. Nuclei were pelleted by centrifugation. The protein concentration in post-
nuclear supernatants was determined by the bicinchoninic acid method as recommended by
the manufacturer (Sigma), using bovine serum albumin as standard. Proteins from cell lysates
or virus purification fractions were separated by SDS-polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes (Hybond-ECL; Amersham) by using a Trans-Blot
apparatus (Bio-Rad). The proteins of interest were revealed with specific primary antibodies,
followed by species-specific secondary antibodies conjugated to horseradish peroxidase (Jack-
son Immunoresearch), and enhanced chemiluminescence detection as recommended by the
manufacturer (Thermofischer).
Sphingomyelinase and methyl-β cyclodextrin treatments
Unpurified BVDV was incubated in culture medium for 1 h at 37°C with sphingomyelinase
from Bacillus cereus (Sigma S7651) at various concentrations. Treated virus was then diluted
1,000 times in culture medium before infecting MDBK cells.
Partially purified BVDV (15–30% sucrose interface) was incubated in culture medium for 1
h at 37°C in the presence of various concentrations of methyl-β-cyclodextrin. Treated virus
was then either diluted 10,000 times in culture medium and used to infect MDBK cells, or
diluted 100 times in DMEM containing various concentrations of cholesterol:methyl-β-cyclo-
dextrin complex and incubated for 1 h at 37°C in order to reload methyl-β-cyclodextrin-treated
virus with cholesterol. Treated virus was diluted 100 times before infecting MDBK cells.
To quantify the impact of sphingomyelinase and methyl-β-cyclodextrin treatments on
BVDV infectivity, MDBK cells (10000 cells per well of 96-well plate) were infected for 1 h at
37°C with 100 μl of treated or control virus. The virus was removed and the cells were overlaid
with 100 μl of fresh culture medium. Cells were fixed 15 h later with 3% paraformaldhehyde in
PBS and processed for immunofluorescent detection of NS3. Nuclei were stained with DAPI.
Samples were observed with a Zeiss Axiophot microscope equipped with a 10 X magnification
objective. Fluorescent signals were collected with a Coolsnap ES camera (Photometrix). For
quantification, images of randomly picked areas from each well were recorded and processed
using ImageJ software. The total number of cells was obtained from DAPI-labeled nuclei.
NS3-positive cells were counted as infected cells. The infection was scored as ratio of infected
cells to total cells.
To assess the impact of sphingomyelinase and methyl-β-cyclodextrin treatments on BVDV
structure, purified BVDV eluted from the cellulose-sulfate column was incubated at 37°C with
sphingomyelinase (1 U/ml) or methyl-β-cyclodextrin (2.5 or 5 mg/ml) or the same volume of
PBS (sphingomyelinase and methyl-β-cyclodextrin solvent). Treated virus was then transferred
on ice and kept at 4°C until cryo-electron microscopy analysis. A small volume was removed
for verifying the impact of treatments on infectivity.
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Analysis of detergent-resistant membranes of infected cells and viral
particles
Lipid rafts were isolated by standard procedures. Infected MDBK cells were grown 150-mm dish
to reach confluence. Cells were rinsed with cold PBS and lysed in 1 ml of TNE containing 0.8% Tri-
ton X-100, and supplemented with protease inhibitors (Roche). Lysates were scraped off the dish
with a cell lifter, the dish was rinsed with 1 ml of the same buffer at 4°C, and the lysate was homog-
enized in a dounce homogenizer. The extract was finally brought up to 40% sucrose in a final vol-
ume of 4 ml and sequentially overlaid with 5 ml of 30% sucrose and 3 ml of 5% sucrose. Gradients
were centrifuged for 18 h at 40,000 rpm at 4°C in a Beckman SW41 rotor. Fractions (1 ml) were
collected from the bottom of the gradient and immediately supplemented with 20μl of a fresh 50X
solution of protease inhibitors. Aliquots of each fraction were analyzed by immunoblotting.
Supporting Information
S1 Text. Supplementary methods and table A.
(DOCX)
S1 Table. Results of lipid quantification.
(XLSX)
S1 Fig. Gallery of cryo-electron microscopy images of purified BVDV fractions.
(PDF)
S2 Fig. Comparative analysis of purified BVDV and control fractions. Cryo-electron
microscopy analysis of purified BVDV (top panels) and a corresponding control fraction puri-
fied from non-infected MDBK cells (bottom panels). Bars, 1 μm (left panels) or 100 nm (right
panels).
(PDF)
S3 Fig. Immunogold electron microscopy of purified BVDV particles. Purified BVDV parti-
cles were labeled with (top panels) or without (bottom panels) anti-E2 mAbs, before negative
staining. Arrowheads indicate colloidal gold particles bound on viral particles. Bars, 100 nm.
(PDF)
S4 Fig. Neutralization of purified and unpurified BVDV with anti-E2 mAbs. Error bars cor-
respond to SDs (n = 4).
(PDF)
S5 Fig. Cryo-electron microscopy analysis of flow-through and elution fractions of cellu-
lose-sulfate chromatography. (A-D) Flow-through fraction. (E, F) 0.4 M NaCl elution frac-
tion. Bars, 500 nm (A) or 100 nm (B,D). Bars, 500 nm (A) or 100 nm (B).
(PDF)
S6 Fig. Cryo-electron microscopy analysis of purified BVDV particles of cytopathic strain
NADL. Bars, 500 nm (top panels) or 100 nm (bottom panels).
(PDF)
S7 Fig. Cryo-electron microscopy images of purified NADL particles incubated at pH 5.1
in the presence of 10 mMDTT.
(PDF)
S8 Fig. Immunoblot analysis of E2 under non-reduced condition in NADL particles purifi-
cation samples.
(PDF)
BVDV Purification
PLOS Pathogens | DOI:10.1371/journal.ppat.1005476 March 3, 2016 25 / 30
S9 Fig. Identification of E2 by mass spectrometry. (A) Annotated mass spectrum of trypsin
digest of ~55 kDa fraction. Peptides assigned to E2 are indicated. (B) Protein view, peptides
matching the sequence are represented as gray bars,
(PDF)
S10 Fig. Lipid composition of purified BVDV and control fractions. The content of individ-
ual lipid classes of purified BVDV (uncorrected for background) and control fractions similarly
purified from non-infected cells are indicated (A) in absolute amounts within the samples and
(B) in relative amounts. Glycerophospholipids: phosphatidic acid (PA), phosphatidylcholine/-
ethanolamine/-glycerol/-inositol/-serine (PC/PE/PG/PI/PS), and ether linked PC/PE (ePC/
ePE). Sphingolipids: ceramide (Cer), sphingomyelin (SM) and hexosylceramide (HexCer). Ste-
rols: cholesterol (Chol). Storage neutral lipids: cholesteryl esters (CE), diacylglycerol (DAG)
and triacylglycerol (TAG). Error bars correspond to SDs (n = 2).
(PDF)
S11 Fig. Species of main phospholipids and sphingolipids of BVDV and MDBK cells. Satu-
ration as a number of double bonds in both fatty acyl chains in (A) phosphatidylethanolamine
(PE), (B) ether linked PE (ePE), (C) ethanolamine plasmalogen (pl-PE), (D) ether linked phos-
phatidylcholine (ePC), (E) phosphatidylserine (PS) (F) phosphatidylinositol (PI), (G) sphingo-
myelin (SM) and (H) hexosylceramide (HexCer) are indicated. Error bars correspond to SDs
(n = 3).
(PDF)
S12 Fig. Control experiments of sphingomyelinase and methyl-β-cyclodextrin treatments.
(A) MDBK cells were infected with BVDV pre-treated with sphingomyelinase as explained in
the legend of Fig 9 (blue bars), incubated with SMase for 2 h and infected with untreated
BVDV (red bars), incubated with untreated BVDV and then incubated with SMase for 2 h, or
infected with BVDV in the presence of SMase without preincubation of BVDV and SMase. (B)
Partially purified BVDV was incubated or not at 37°C for 1 h with 5mg/ml methyl-β-cyclodex-
trin (MBCD), diluted 10,000 times and used to infect MDBK cells. The number of infected
cells was measured using an immunofluorescence assay at 15 hpi and standardized to the num-
ber of cells infected with untreated virus.
(PDF)
S13 Fig. Cryo-electron microscopy analysis purified BVDV treated with sphingomyelinase
or methyl-β-cyclodextrin. Purified BVDV was incubated for 1 h at 37°C with (A) no treat-
ment, (B) 1U/ml SMase, (C) 2.5 mg/ml MBCD, or (D) 5 mg/ml MBCD, and analyzed by cryo-
electron microscopy. Insets, low magnification image. Bars, 500 nm (insets) or 100 nm (main
image).
(PDF)
S14 Fig. Cryo-electron microscopy image of BVDV-derived aggregates induced by 5mg/ml
methyl-β-cyclodextrin. Purified BVDV was incubated for 1 h at 37°C with 5 mg/ml MBCD,
and analyzed by cryo-electron microscopy. Inset, high magnification image. Bars, 500 nm
(main image) or 100 nm (inset).
(PDF)
Acknowledgments
We are grateful to Sophana Ung for his assistance in the illustrations. We also thank G. Cha-
puis, G. Meyers, P.P. Pastoret, C.M. Rice, for providing us with reagents. Some data were
BVDV Purification
PLOS Pathogens | DOI:10.1371/journal.ppat.1005476 March 3, 2016 26 / 30
generated with the help of the Imaging Core Facility of the campus Calmette (BICeL). We
thank the Chemistry Systems Biology facility for its technical advice and support.
Author Contributions
Conceived and designed the experiments: NC BB PB HD OL JD YR. Performed the experi-
ments: NC BB PB HDMJG. Analyzed the data: NC BB PB HD OL YR. Contributed reagents/
materials/analysis tools: TK GRS TR. Wrote the paper: NC BB PB OL YR.
References
1. Lindenbach BD, Thiel H-J, Rice CM. Flaviviridae: the viruses and their replication. Knipe DM, Howley
PM, editors. Fields Virology. 5 ed. Philadelphia; 2007;: 1101–1152.
2. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encepha-
litis virus at 2 A resolution. Nature. 1995; 375: 291–298. doi: 10.1038/375291a0 PMID: 7753193
3. Kuhn RJ, ZhangW, RossmannMG, Pletnev SV, Corver J, Lenches E, et al. Structure of dengue virus:
implications for flavivirus organization, maturation, and fusion. Cell. 2002; 108: 717–725. PMID:
11893341
4. Bartenschlager R, Penin F, Lohmann V, André P. Assembly of infectious hepatitis C virus particles.
Trends Microbiol. 2011; 19: 95–103. doi: 10.1016/j.tim.2010.11.005 PMID: 21146993
5. Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Micro.
2013; 11: 688–700. doi: 10.1038/nrmicro3098
6. Merz A, Long G, Hiet M-S, Brügger B, Chlanda P, André P, et al. Biochemical and morphological prop-
erties of hepatitis C virus particles and determination of their lipidome. J Biol Chem. 2011; 286: 3018–
3032. doi: 10.1074/jbc.M110.175018 PMID: 21056986
7. Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, RiceWJ, et al. Ultrastructural analysis of hepati-
tis C virus particles. Proc Natl Acad Sci USA. 2013; 110: 9505–9510. doi: 10.1073/pnas.1307527110
PMID: 23690609
8. Scholtes C, Ramière C, Rainteau D, Perrin-Cocon L, Wolf C, Humbert L, et al. High plasma level of
nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology.
2012; 56: 39–48. doi: 10.1002/hep.25628 PMID: 22290760
9. Icard V, Diaz O, Scholtes C, Perrin-Cocon L, Ramière C, Bartenschlager R, et al. Secretion of hepatitis
C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS
ONE. 2009; 4: e4233. doi: 10.1371/journal.pone.0004233 PMID: 19156195
10. Omari El K, Iourin O, Harlos K, Grimes JM, Stuart DI. Structure of a pestivirus envelope glycoprotein E2
clarifies its role in cell entry. Cell Rep. 2013; 3: 30–35. doi: 10.1016/j.celrep.2012.12.001 PMID:
23273918
11. Li Y, Wang J, Kanai R, Modis Y. Crystal structure of glycoprotein E2 from bovine viral diarrhea virus.
Proc Natl Acad Sci USA. 2013; 110: 6805–6810. doi: 10.1073/pnas.1300524110 PMID: 23569276
12. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, et al. Hepatitis C virus e2 envelope gly-
coprotein core structure. Science. 2013; 342: 1090–1094. doi: 10.1126/science.1243876 PMID:
24288331
13. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, et al. Structure of the core ecto-
domain of the hepatitis C virus envelope glycoprotein 2. Nature. 2014; 509: 381–384. doi: 10.1038/
nature13117 PMID: 24553139
14. Tautz N, Tews BA, Meyers G. The Molecular Biology of Pestiviruses. Adv Virus Res. 2015; 93: 47–160.
doi: 10.1016/bs.aivir.2015.03.002 PMID: 26111586
15. Weiland F, Weiland E, Unger G, Saalmüller A, Thiel HJ. Localization of pestiviral envelope proteins E
(rns) and E2 at the cell surface and on isolated particles. J Gen Virol. 1999; 80: 1157–1165. PMID:
10355762
16. Schmeiser S, Mast J, Thiel H-J, König M. Morphogenesis of pestiviruses: new insights from ultrastruc-
tural studies of strain Giraffe-1. J Virol. 2014; 88: 2717–2724. doi: 10.1128/JVI.03237-13 PMID:
24352462
17. Riedel C, Lamp B, Heimann M, König M, Blome S, Moennig V, et al. The core protein of classical Swine
Fever virus is dispensable for virus propagation in vitro. PLoS Pathog. 2012; 8: e1002598. doi: 10.
1371/journal.ppat.1002598 PMID: 22457622
18. Pritchett R, Manning JS, Zee YC. Characterization of bovine viral diarrhea virus RNA. J Virol. 1975; 15:
1342–1347. PMID: 1170338
BVDV Purification
PLOS Pathogens | DOI:10.1371/journal.ppat.1005476 March 3, 2016 27 / 30
19. Laude H. Nonarbo-togaviridae: comparative hydrodynamic properties of the pestivirus genus. Brief
report. Arch Virol. 1979; 62: 347–352. PMID: 232414
20. Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV assembly. Curr Opin
Struct Biol. 2008; 18: 203–217. doi: 10.1016/j.sbi.2008.02.001 PMID: 18406133
21. Bonnafous P, Perrault M, Le Bihan O, Bartosch B, Lavillette D, Penin F, et al. Characterization of hepa-
titis C viral pseudoparticles by cryo-electron microscopy usingfunctionalized magnetic nanobeads.
Journal of General Virology. 2010; 91 (Pt 8): 1919–1930. doi: 10.1099/vir.0.021071–0 PMID: 20375221
22. Krey T, Thiel H-J, Rümenapf T. Acid-resistant bovine pestivirus requires activation for pH-triggered
fusion during entry. J Virol. 2005; 79: 4191–4200. doi: 10.1128/JVI.79.7.4191–4200.2005 PMID:
15767420
23. Weiland E, Stark R, Haas B, Rümenapf T, Meyers G, Thiel HJ. Pestivirus glycoprotein which induces
neutralizing antibodies forms part of a disulfide-linked heterodimer. J Virol. 1990; 64: 3563–3569.
PMID: 2370675
24. Branza-Nichita N, Durantel D, Carrouee-Durantel S, Dwek RA, Zitzmann N. Antiviral effect of N-butyl-
deoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins
and impairment of their association into E1-E2 heterodimers. J Virol. 2001; 75: 3527–3536. doi: 10.
1128/JVI.75.8.3527–3536.2001 PMID: 11264342
25. Thiel HJ, Stark R, Weiland E, Rümenapf T, Meyers G. Hog cholera virus: molecular composition of viri-
ons from a pestivirus. J Virol. 1991; 65: 4705–4712. PMID: 1870198
26. Langedijk JPM, van Veelen PA, Schaaper WMM, de Ru AH, Meloen RH, Hulst MM. A structural model
of pestivirus E(rns) based on disulfide bond connectivity and homology modeling reveals an extremely
rare vicinal disulfide. J Virol. 2002; 76: 10383–10392. PMID: 12239315
27. Simpson RJ, Jensen SS, Lim JWE. Proteomic profiling of exosomes: current perspectives. Proteomics.
2008; 8: 4083–4099. doi: 10.1002/pmic.200800109 PMID: 18780348
28. van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: a common pathway for a specialized
function. J Biochem. 2006; 140: 13–21. doi: 10.1093/jb/mvj128 PMID: 16877764
29. Brügger B, Glass B, Haberkant P, Leibrecht I, Wieland FT, Kräusslich H-G. The HIV lipidome: a raft
with an unusual composition. Proc Natl Acad Sci USA. 2006; 103: 2641–2646. doi: 10.1073/pnas.
0511136103 PMID: 16481622
30. Kalvodova L, Sampaio JL, Cordo S, Ejsing CS, Shevchenko A, Simons K. The lipidomes of vesicular
stomatitis virus, semliki forest virus, and the host plasmamembrane analyzed by quantitative shotgun
mass spectrometry. J Virol. 2009; 83: 7996–8003. doi: 10.1128/JVI.00635-09 PMID: 19474104
31. Gerl MJ, Sampaio JL, Urban S, Kalvodova L, Verbavatz J-M, Binnington B, et al. Quantitative analysis
of the lipidomes of the influenza virus envelope and MDCK cell apical membrane. J Cell Biol. 2012;
196: 213–221. doi: 10.1083/jcb.201108175 PMID: 22249292
32. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat
Rev Mol Cell Biol. 2008; 9: 112–124. doi: 10.1038/nrm2330 PMID: 18216768
33. Lingwood D, Simons K. Lipid Rafts As a Membrane-Organizing Principle. Science. 2010; 327: 46–50.
doi: 10.1126/science.1174621 PMID: 20044567
34. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains
during transport to the apical cell surface. Cell. 1992; 68: 533–544. PMID: 1531449
35. Zhang X, Ge P, Yu X, Brannan JM, Bi G, Zhang Q, et al. Cryo-EM structure of the mature dengue virus
at 3.5-Å resolution. Nat Struct Mol Biol. 2013; 20: 105–110. doi: 10.1038/nsmb.2463 PMID: 23241927
36. Zhang X, Sheng J, Austin SK, Hoornweg TE, Smit JM, Kuhn RJ, et al. Structure of acidic pH dengue
virus showing the fusogenic glycoprotein trimers. J Virol. 2015; 89: 743–750. doi: 10.1128/JVI.02411-
14 PMID: 25355881
37. Battisti AJ, Yoder JD, Plevka P, Winkler DC, Prasad VM, Kuhn RJ, et al. Cryo-electron tomography of
rubella virus. J Virol. 2012; 86: 11078–11085. doi: 10.1128/JVI.01390-12 PMID: 22855483
38. Crowther RA, Kiselev NA, Böttcher B, Berriman JA, Borisova GP, Ose V, et al. Three-dimensional
structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell. 1994; 77:
943–950. PMID: 8004680
39. Wang Z, Nie Y, Wang P, Ding M, Deng H. Characterization of classical swine fever virus entry by using
pseudotyped viruses: E1 and E2 are sufficient to mediate viral entry. Virology. 2004; 330: 332–341. doi:
10.1016/j.virol.2004.09.023 PMID: 15527858
40. Ronecker S, Zimmer G, Herrler G, Greiser-Wilke I, Grummer B. Formation of bovine viral diarrhea virus
E1-E2 heterodimers is essential for virus entry and depends on charged residues in the transmem-
brane domains. J Gen Virol. 2008; 89: 2114–2121. doi: 10.1099/vir.0.2008/001792-0 PMID: 18753220
BVDV Purification
PLOS Pathogens | DOI:10.1371/journal.ppat.1005476 March 3, 2016 28 / 30
41. Yang X, Kurteva S, Ren X, Lee S, Sodroski J. Stoichiometry of envelope glycoprotein trimers in the
entry of human immunodeficiency virus type 1. J Virol. 2005; 79: 12132–12147. doi: 10.1128/JVI.79.19.
12132–12147.2005 PMID: 16160141
42. Magnus C, Rusert P, Bonhoeffer S, Trkola A, Regoes RR. Estimating the stoichiometry of human
immunodeficiency virus entry. J Virol. 2009; 83: 1523–1531. doi: 10.1128/JVI.01764-08 PMID:
19019953
43. Le Duff Y, Blanchet M, Sureau C. The pre-S1 and antigenic loop infectivity determinants of the hepatitis
B virus envelope proteins are functionally independent. J Virol. 2009; 83: 12443–12451. doi: 10.1128/
JVI.01594-09 PMID: 19759159
44. Ivanovic T, Choi JL, Whelan SP, van Oijen AM, Harrison SC. Influenza-virus membrane fusion by coop-
erative fold-back of stochastically induced hemagglutinin intermediates. Elife. 2013; 2: e00333. doi: 10.
7554/eLife.00333 PMID: 23550179
45. Rümenapf T, Unger G, Strauss JH, Thiel HJ. Processing of the envelope glycoproteins of pestiviruses.
J Virol. 1993; 67: 3288–3294. PMID: 8388499
46. Chan R, Uchil PD, Jin J, Shui G, Ott DE, MothesW, et al. Retroviruses human immunodeficiency virus
and murine leukemia virus are enriched in phosphoinositides. J Virol. 2008; 82: 11228–11238. doi: 10.
1128/JVI.00981-08 PMID: 18799574
47. Pike LJ, Han X, Chung K-N, Gross RW. Lipid rafts are enriched in arachidonic acid and plasmenyletha-
nolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray
ionization/mass spectrometric analysis. Biochemistry. 2002; 41: 2075–2088. doi: 10.1021/bi0156557
PMID: 11827555
48. Greiser-Wilke I, Dittmar KE, Liess B, Moennig V. Immunofluorescence studies of biotype-specific
expression of bovine viral diarrhoea virus epitopes in infected cells. J Gen Virol. 1991; 72: 2015–2019.
doi: 10.1099/0022-1317-72-8-2015 PMID: 1714946
49. Köhl W, Zimmer G, Greiser-Wilke I, Haas L, Moennig V, Herrler G. The surface glycoprotein E2 of
bovine viral diarrhoea virus contains an intracellular localization signal. J Gen Virol. 2004; 85: 1101–
1111. doi: 10.1099/vir.0.19740–0 PMID: 15105527
50. Macovei A, Zitzmann N, Lazar C, Dwek RA, Branza-Nichita N. Brefeldin A inhibits pestivirus release
from infected cells, without affecting its assembly and infectivity. Biochem Biophys Res Commun.
2006; 346: 1083–1090. doi: 10.1016/j.bbrc.2006.06.023 PMID: 16782064
51. van Meer G, de Kroon AIPM. Lipid map of the mammalian cell. J Cell Sci. 2011; 124: 5–8. doi: 10.1242/
jcs.071233 PMID: 21172818
52. Martín-Acebes MA, Merino-Ramos T, Blázquez A- B, Casas J, Escribano-Romero E, Sobrino F, et al.
The composition of West Nile virus lipid envelope unveils a role of sphingolipid metabolism in flavivirus
biogenesis. J Virol. 2014; 88: 12041–12054. doi: 10.1128/JVI.02061-14 PMID: 25122799
53. Weiskircher E, Aligo J, Ning G, Konan KV. Bovine viral diarrhea virus NS4B protein is an integral mem-
brane protein associated with Golgi markers and rearranged host membranes. Virol J. 2009; 6: 185.
doi: 10.1186/1743-422X-6-185 PMID: 19887001
54. Browman DT, Resek ME, Zajchowski LD, Robbins SM. Erlin-1 and erlin-2 are novel members of the
prohibitin family of proteins that define lipid-raft-like domains of the ER. J Cell Sci. 2006; 119: 3149–
3160. doi: 10.1242/jcs.03060 PMID: 16835267
55. Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. Sigma-1 receptor regulates early
steps of viral RNA replication at the onset of hepatitis C virus infection. J Virol. 2013; 87: 6377–6390.
doi: 10.1128/JVI.03557-12 PMID: 23536676
56. Krey T, Moussay E, Thiel H-J, Rümenapf T. Role of the low-density lipoprotein receptor in entry of
bovine viral diarrhea virus. J Virol. 2006; 80: 10862–10867. doi: 10.1128/JVI.01589-06 PMID:
16928760
57. Mendez E, Ruggli N, Collett MS, Rice CM. Infectious bovine viral diarrhea virus (strain NADL) RNA
from stable cDNA clones: a cellular insert determines NS3 production and viral cytopathogenicity. J
Virol. 1998; 72: 4737–4745. PMID: 9573238
58. Lamp B, Riedel C, Roman-Sosa G, Heimann M, Jacobi S, Becher P, et al. Biosynthesis of classical
swine fever virus nonstructural proteins. J Virol. 2011; 85: 3607–3620. doi: 10.1128/JVI.02206-10
PMID: 21270154
59. Boulanger D, Waxweiler S, Karelle L, Loncar M, Mignon B, Dubuisson J, et al. Characterization of
monoclonal antibodies to bovine viral diarrhoea virus: evidence of a neutralizing activity against gp48 in
the presence of goat anti-mouse immunoglobulin serum. J Gen Virol. 1991; 72: 1195–1198. doi: 10.
1099/0022-1317-72-5-1195 PMID: 1851819
BVDV Purification
PLOS Pathogens | DOI:10.1371/journal.ppat.1005476 March 3, 2016 29 / 30
60. Özbalci C, Sachsenheimer T, Brügger B. Quantitative Analysis of Cellular Lipids by Nano-Electrospray
Ionization Mass Spectrometry. gate1inistfr. Totowa, NJ: Humana Press; 2013. pp. 3–20. doi: 10.1007/
978-1-62703-487-6_1
61. Paltauf F, Hermetter A. Strategies for the synthesis of glycerophospholipids. Prog Lipid Res. 1994; 33:
239–328. PMID: 8022845
BVDV Purification
PLOS Pathogens | DOI:10.1371/journal.ppat.1005476 March 3, 2016 30 / 30
